P50 suppression and its neural generators in antipsychotic-Naïve first-episode schizophrenia before and after 6 months of quetiapine treatment

Schizophrenia Bulletin

Volumn 39, Issue 2, 2013, Pages 472-480

  Oranje, Bob ^a,b   Aggernaes, Bodil ^a   Rasmussen, Hans ^a   Ebdrup, Bjorn H ^a   Glenthøj, Birte Y ^a,b  

^a Mental Health Center Glostrup   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

antipsychotic na ve; first episode; quetiapine; schizophrenia; sensory gating; source localization

Indexed keywords

ANTIDEPRESSANT AGENT; QUETIAPINE;

ADULT; AMPLITUDE MODULATION; ARTICLE; AUDITORY RESPONSE; COMPUTER ANALYSIS; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ELECTROENCEPHALOGRAPHY; FEMALE; FOLLOW UP; HEARING; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; P50 AMPLITUDE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SENSORY GATING;

ACOUSTIC STIMULATION; ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; CASE-CONTROL STUDIES; DIBENZOTHIAZEPINES; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; MALE; SCHIZOPHRENIA; SENSORY GATING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874533482     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbr183     Document Type: Article

References (39)

1. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia: human and animal model studies. Arch Gen Psychiatry. 1990;47:181-188. (Pubitemid 20058094)
2. Freedman R, Waldo MC, Bickford-Wimer PC, Nagamoto H. Elementary neuronal dysfunctions in schizophrenia. Schizophr Res. 1991;4:233-243.
3. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry. 1982;17:639-654. (Pubitemid 12090209)
4. Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res. 2004;70:315-329. (Pubitemid 39141109)
5. Arnfred SM, Chen AC, Glenthoj BY, Hemmingsen RP. Normal p50 gating in unmedicated schizophrenia outpatients. Am J Psychiatry. 2003;160:2236-2238. (Pubitemid 39619621)
6. Freedman R, Adler LE, Waldo MC, Pachtman E, Franks RD. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol Psychiatry. 1983;18:537-551. (Pubitemid 13135325)
7. Yee CM, Nuechterlein KH, Morris SE, White PM. P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. J Abnorm Psychol. 1998;107:691-698. (Pubitemid 28527584)
8. deWilde OM, Bour LJ, Dingemans PM, Koelman JH, Linszen DH. Failure to find P50 suppression deficits in young firstepisode patients with schizophrenia and clinically unaffected siblings. Schizophr Bull. 2007;33:1319-1323. (Pubitemid 350022766)
9. Hong X, Chan RC, Zhuang X, et al. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia. Schizophr Res. 2009;108:151-157.
10. Brockhaus-Dumke A, Schultze-Lutter F, Mueller R, et al. Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients. Biol Psychiatry. 2008;64:376-384.
11. Boutros NN, Zouridakis G, Rustin T, Peabody C. The P50 component of the auditory evoked potential and subtypes of schizophrenia. Psychiatry Res. 1993;47:243-254. (Pubitemid 23190383)
12. Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae KA, Freedman R. Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol Psychiatry. 1996;40:181-188. (Pubitemid 26349110)
13. Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry. 2000;157:767-771. (Pubitemid 30249656)
14. Adler LE, Olincy A, Cawthra EM, et al. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry. 2004;161:1822-1828. (Pubitemid 39314676)
15. Potter D, Summerfelt A, Gold J, Buchanan RW. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull. 2006;32:692-700. (Pubitemid 44412856)
16. Oranje B, Wienberg M, Glenthoj BY. A single high dose of escitalopram disrupts sensory gating and habituation, but not sensorimotor gating in healthy volunteers. Psychiatry Res. 2011;186:431-436.
17. Oranje B, Gispen-de Wied CC, Verbaten MN, Kahn RS. Modulating sensory gating in healthy volunteers. The effects of ketamine and haloperidol. Biol Psychiatry. 2002;52: 887-895. (Pubitemid 35223432)
18. Csomor PA, Stadler RR, Feldon J, Yee BK, Geyer MA, Vollenweider FX. Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology. 2008;33:497-512.
19. Bickford-Wimer PC, Nagamoto H, Johnson R, Adler LE. Auditory sensory gating in hippocampal neurons: A model system in the rat. Biol Psychiatry. 1990;27:183-192. (Pubitemid 20033766)
20. Freedman R, Olincy A, Ross RG, et al. The genetics of sensory gating deficits in schizophrenia. Curr Psychiatry Rep. 2003;5:155-161. (Pubitemid 38899215)
21. Oranje B, Geyer MA, Kenemans JL, Verbaten MN. Prepulse inhibition and P50 suppression: commonalities and dissociations. Psychiatry Res. 2006;143:147-158 (Pubitemid 44301523)
22. Jensen KS, Oranje B, Wienberg M, Glenthoj BY. The effects of increased serotonergic activity on human sensory gating and its neural generators. Psychopharmacology (Berl). 2008;196:631-641.
23. Knott V,Millar A, Fisher D. Sensory gating and source analysis of the auditory P50 in low and high suppressors. Neuroimage. 2009;44:992-1000.
24. Weisser R, Weisbrod M, Roehrig M, Rupp A, Schroeder J, Scherg M. Is frontal lobe involved in the generation of auditory evoked P50? Neuroreport. 2001;12:3303-3307. (Pubitemid 33010661)
25. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000;57:553-559. (Pubitemid 30349435)
26. Tauscher J, Hussain T, Agid O, et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry. 2004;161:1620-1625. (Pubitemid 39201459)
27. Wing JK, Babor T, Brugha T, et al. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry. 1990;47:589-593. (Pubitemid 20189971)
28. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276. (Pubitemid 18039085)
29. Oranje B, Jensen K, Wienberg M, Glenthoj BY. Divergent effects of increased serotonergic activity on psychophysiological parameters of human attention. Int J Neuropsychopharmacol. 2008;11:453-463. (Pubitemid 351744803)
30. Metting van Rijn AC, Kuiper AP, Dankers TE, Grimbergen CA. Low-cost active electrode improves the resolution in biopotential recordings. 1996; Proceedings of the 18th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Amsterdam, The Netherlands, Track 1 2 3-3.
31. Berg P, Scherg M. A multiple source approach to the correction of eye artifacts. Electroencephalogr Clin Neurophysiol. 1994;90:229-241. (Pubitemid 24090795)
32. Adler LE, Hoffer LJ, Griffith J, Waldo MC. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry. 1992;32:607-616.
33. De Luca V, Wong AH, Muller DJ, Wong GW, Tyndale RF, Kennedy JL. Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacology. 2004;29:1522-1526. (Pubitemid 38982245)
34. Arango C, Summerfelt A, Buchanan RW. Olanzapine effects on auditory sensory gating in schizophrenia. Am J Psychiatry. 2003;160:2066-2068. (Pubitemid 39619651)
35. Nagamoto HT, Adler LE, McRae KA, et al. Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol. Neuropsychobiology. 1999;39:10-17. (Pubitemid 29037759)
36. Grunwald T, Boutros NN, Pezer N, et al. Neuronal substrates of sensory gating within the human brain. Biol Psychiatry. 2003;53:511-519. (Pubitemid 36331890)
37. Korzyukov O, Pflieger ME, Wagner M, et al. Generators of the intracranial P50 response in auditory sensory gating. Neuroimage. 2007;35:814-826. (Pubitemid 46420427)
38. Weiland BJ, Boutros NN, Moran JM, Tepley N, Bowyer SM. Evidence for a frontal cortex role in both auditory and somatosensory habituation: a MEG study. Neuroimage. 2008;42:827-835.
39. Bak N, Glenthoj BY, Rostrup E, Larsson H, Oranje B. Source localization of sensory gating: a combined EEG and fMRI study in healthy volunteers. Neuroimage. 2010; 54:2711-2718.